Biology subjects

Caron, M. G.

Publications and source records attributed to Caron, M. G..

5 recordsLinked to original sources

bioRxiv2024

Combination of Haloperidol with UNC9994, β-arrestin-biased analog of Aripiprazole, ameliorates schizophrenia-related phenotypes induced by NMDAR deficit in mice.

BackgroundGlutamatergic system dysfunction, particularly involving the N-methyl-D-aspartate receptor (NMDAR), contributes to a full spectrum of schizophrenia-like symptoms, including the cognitive and negative symptoms that are resistant to treatment with antipsychotic drugs (APDs). Aripiprazole, an atypical antipsychotic drug (APD), acts as a dopamine partial agonist and its combination with haloperidol (a typical APD) has been suggested as a potential strategy to improve schizophrenia symptoms. Recently, an analog of aripiprazole - UNC9994 was developed. UNC9994 does not affect D2R-mediated Gi/o protein signaling but acts as a partial agonist for D2R/{beta}-arrestin interactions. Hence, our objective was to probe the effects of co-administrating haloperidol with UNC9994 in NMDAR mouse models of schizophrenia. MethodsNMDAR hypofunction was induced pharmacologically by acute injection of MK-801 (NMDAR pore blocker; 0.15 mg/kg) and genetically by knockdown of Grin1 gene expression in mice, which have a 90% reduction in NMDAR levels (Grin1-KD). After intraperitoneal injections of vehicle, haloperidol (0.15 mg/kg), UNC9994 (0.25 mg/kg) or their combination mice were tested in open field, Pre-Pulse inhibition (PPI), Y-maze and Puzzle box. ResultsOur findings indicate that low dose co-administration of UNC9994 and haloperidol reduces hyperactivity in MK-801-treated animals and in Grin1-KD mice. Furthermore, this dual administration effectively reverses PPI deficits, repetitive/rigid behavior in the Y-maze, and deficient executive function in the Puzzle box in both animal models. ConclusionsThe dual administration of haloperidol with UNC9994 at low doses represents a promising approach to ameliorate positive, negative, and cognitive symptoms of schizophrenia. Significance statementSchizophrenia is a devastating mental disorder and characterized by positive, negative, and cognitive symptoms. Cognitive and negative symptoms remain a focus of research dedicated to development of effective antipsychotic drugs (APDs). Aripiprazole, an atypical APD, acts as a dopamine partial agonist and its combination with haloperidol (a typical APD) has been suggested as a potential strategy to improve schizophrenia symptoms. An analog of aripiprazole - UNC9994 was recently developed, which does not affect D2R-mediated Gi/o protein signaling but acts as a partial agonist for D2R/{beta}-arrestin interactions. Our pre-clinical findings on pharmacological (MK-801, 0.15 mg/kg) and genetic (Grin1-KD) mouse models of NMDAR deficiency showed that the dual administration of UNC9994 (0.25 mg/kg) with haloperidol (0.15 mg/kg) at low doses reduces hyperactivity, corrects prepulse inhibition (PPI) deficits, rigid behavior in the Y-maze, and deficient executive function in the Puzzle box. Further studies of the polypharmacy of UNC9994 with APDs is essential to facilitate translational studies in clinics.

pharmacology and toxicology↗

bioRxiv2022

Neurotensin receptor allosterism revealed in complex with a biased allosteric modulator

The NTSR1 neurotensin receptor (NTSR1) is a G protein coupled receptor (GPCR) found in the brain and peripheral tissues with neurotensin (NTS) being its endogenous peptide ligand. In the brain, NTS modulates dopamine neuronal activity, induces opioid-independent analgesia, and regulates food intake. Recent studies indicate that biasing NTSR1 toward {beta}-Arrestin signaling can attenuate the actions of psychostimulants and other drugs of abuse. Here we provide the cryoEM structures of NTSR1 ternary complexes with heterotrimeric Gq and Go with and without the brain penetrant small molecule SBI-553. In functional studies, we discovered that SBI-553 displays complex allosteric actions exemplified by negative allosteric modulation for G proteins that are G subunit selective and positive allosteric modulation and agonism for {beta}-Arrestin translocation at NTSR1. Detailed structural analysis of the allosteric binding site illuminated the structural determinants for biased allosteric modulation of SBI-553 on NTSR1. These insights promise to both accelerate the structure-guided design of more effective NTSR1 therapeutics and provide insights into the complexities of GPCR allosteric modulation.

biophysics↗

bioRxiv2020

Establishment of Multi-stage Models of Drug Taking and Seeking in Mice

A genetically tractable animal model would provide a needed strategy to resolve the biological basis of drug addiction. Intravenous self-administration (IVSA) is the gold standard for modeling cocaine and opioid addiction in animals, but technical limitations have precluded the widespread use of IVSA in mice. Here, we describe the first IVSA paradigms for mice that capture the multi-stage nature of the disease and permit predictive modeling. Mice with long-standing indwelling jugular catheters engaged in cocaine or opioid-associated lever responding that was fixed ratio- and dose-dependent, extinguished by the withholding of drug, and reinstated by the presentation of paired cues. Machine learning revealed that vulnerability to drug seeking and relapse were predicted by a mouses a priori response to novelty, sensitivity to drug-induced locomotion, and drug-taking behavior. Application of this behavioral and analysis approach to genetically-engineered mice will facilitate the identification of the neural circuits driving addiction susceptibility and relapse and focused therapeutic development.

neuroscience↗

bioRxiv2019

Loss of β-arrestin2 in D2 cells alters neuronal excitability in the nucleus accumbens and behavioral responses to psychostimulants and opioids

Psychostimulants and opioids increase dopamine (DA) neurotransmission, activating D1 and D2 G protein-coupled receptors. {beta}-arrestin2 ({beta}arr2) desensitizes and internalizes these receptors and initiates G protein-independent signaling. Previous work revealed that mice with a global or cell-specific knockout of {beta}arr2 have altered responses to certain drugs; however, the effects of {beta}arr2 on the excitability of medium spiny neurons (MSNs) and its role in mediating the rewarding effects of drugs of abuse are unknown. D1-Cre and D2-Cre transgenic mice were crossed with floxed {beta}arr2 mice to eliminate {beta}arr2 specifically in cells containing either D1 (D1{beta}arr2-KO) or D2 (D2{beta}arr2-KO) receptors. We used slice electrophysiology to characterize the role of {beta}arr2 in modulating D1 and D2 nucleus accumbens MSN intrinsic excitability in response to DA and tested the locomotor-activating and rewarding effects of cocaine and morphine in these mice. We found that eliminating {beta}arr2 attenuated the ability of DA to inhibit D2-MSNs but had little effect on the DA response of D1-MSNs. While D1{beta}arr2-KO mice had mostly normal drug responses, D2{beta}arr2-KO mice showed dose-dependent reductions in acute locomotor responses to cocaine and morphine, attenuated locomotor sensitization to cocaine, and blunted cocaine reward measured with conditioned place preference. Both D2{beta}arr2-KO and D1{beta}arr2-KO mice displayed an enhanced conditioned place preference for the highest dose of morphine. These results indicate that D2-derived {beta}arr2 functionally contributes to the ability of DA to inhibit D2-MSNs and multiple behavioral responses to psychostimulants and opioids, while loss of {beta}arr2 in D1 neurons has little impact on D1-MSN excitability or drug-induced behaviors.

neuroscience↗

bioRxiv2019

Noncanonical scaffolding of Gαi and β-arrestin by G protein-coupled receptors

G-protein-coupled receptors (GPCRs) enable cells to sense and respond appropriately to hormonal and environmental signals, and are a target of ~30% of all FDA-approved medications. Canonically, each GPCR couples to distinct G proteins, such as Gs, Gi, Gq or G12/13, as well as {beta}-arrestins. These transducer proteins translate and integrate extracellular stimuli sensed by GPCRs into intracellular signals through what are broadly considered separable signalling pathways. However, the ability of G proteins to directly interact with {beta}-arrestins to integrate signalling has not previously been appreciated. Here we show a novel interaction between Gi protein family members and {beta}-arrestin. Gi:{beta}-arrestin complexes were formed by all GPCRs tested, regardless of their canonical G protein isoform coupling, and could bind both GPCRs as well as the extracellular signal-regulated kinase (ERK). This novel paradigm of Gi:{beta}-arrestin scaffolds enhances our understanding of GPCR signalling.

cell biology↗